Literature DB >> 22923770

Is the human sex ratio at birth a sentinel health indicator that is associated with HIV/AIDS and tuberculosis prevalences in the 21st century?

Anna Shifotoka1, Andrew W Fogarty.   

Abstract

BACKGROUND: A reduction in sex ratio at live birth has been proposed as a sentinel health indicator that can be used to monitor the health of populations.
OBJECTIVE: To test the hypothesis that a lower sex ratio is associated with adverse national population health using the prevalences of HIV and tuberculosis as measures of societal well-being.
METHODS: An ecological study design using routinely collected data and adjusting for potential confounding factors.
RESULTS: The mean global sex ratio was 1.05. There was marked heterogeneity in the sex ratio between different global regions (p<0.0001). Those regions with the highest prevalences of HIV infection had lower sex ratios, with the value for the highest quartile being 0.022 (95% CIs CI 0.013 to 0.031) lower than the lowest quartile. Similarly, those areas with the highest quartile of tuberculosis infection had a sex ratio of 0.016 (95% CI 0.004 to 0.028) lower than those in the lowest quartile. Similar results were observed in a subgroup analysis limited to countries from the African continent.
CONCLUSIONS: The data are consistent with the hypothesis that a reduced sex ratio at live birth is a potential sentinel health indicator of lower population health. However, these data do not demonstrate either a casual relationship or reveal any biological mechanisms that may account for these observations.

Entities:  

Mesh:

Year:  2012        PMID: 22923770     DOI: 10.1136/jech-2011-200744

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  1 in total

1.  Is the mothers' country of birth associated with the sex of their offspring in England and Wales from 2007 to 2011?

Authors:  Cameron Smith; Andrew Fogarty
Journal:  BMC Pregnancy Childbirth       Date:  2014-09-25       Impact factor: 3.007

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.